ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
14.83
+0.21 (1.44%)
Apr 24, 2025, 4:00 PM EDT - Market closed
ACADIA Pharmaceuticals Revenue
In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth. ACADIA Pharmaceuticals had revenue of $259.60M in the quarter ending December 31, 2024, with 12.36% growth.
Revenue (ttm)
$957.80M
Revenue Growth
+31.85%
P/S Ratio
2.57
Revenue / Employee
$1,464,521
Employees
654
Market Cap
2.47B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ACAD News
- 1 day ago - Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - Business Wire
- 13 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med - Business Wire
- 7 weeks ago - Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - Business Wire
- 7 weeks ago - Acadia Pharmaceuticals Ends FY2024 On Solid Footing - Seeking Alpha
- 2 months ago - Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference - Business Wire
- 2 months ago - ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript - Seeking Alpha